Gruns raises at up to $500M valuation as gummy supplement startups boom
Apr 21, 2025
Key Points
- Gruns raises $10M at $500M valuation on $10M monthly revenue, trading at a 5x multiple that reflects strong unit economics rather than exceptionalism for high-growth startups.
- The gummy supplement category is booming as competitors like Goalie generate hundreds of millions annually, while quality issues in Amazon products create an opening for brands that deliver on label claims.
- Gruns targets weight-loss drug users with digital ads positioning gummies as a way to maintain nutrients during caloric deficits, capitalizing on the Ozempic boom as a new marketing angle.
Summary
Gruns, a two-year-old gummy supplement startup, raised approximately $10M at a $500M valuation in recent weeks. The round represents low dilution for a company hitting $10M in monthly revenue earlier this year.
Gruns positions itself as a cheaper, more convenient alternative to greens powders. The company sells a monthly supply of gummy vitamins for $79, or $59 for subscribers, with more than 60 vitamins, minerals, and other ingredients in a single serving. It recently expanded into kids products and sugar-free versions.
The founder, Chad, previously worked at Summit Partners and sits on the boards of scaled consumer brands including Ruggable, Dr. Squatch, Brooklyn, and Solo Stove. His track record optimizing consumer product unit economics appears central to Gruns' traction.
Gruns is capitalizing on two market tailwinds. The appetite for supplement gummies remains strong. Goalie, which makes apple cider vinegar gummies, generates hundreds of millions in annual revenue with 364,000 Amazon reviews. The weight-loss drug boom creates a second angle. Gruns has run digital ads targeting people taking Ozempic who want to maintain nutrient intake as appetite fades. Users on caloric deficits need to preserve muscle mass and micronutrient levels.
The broader gummy supplement category is booming. Create Wellness, which makes creatine gummies, raised $5M in Series A funding last fall and is on pace for around $25M in annual revenue. Quality issues plague many Amazon products in the space, with some containing little to no actual active ingredient. That gap creates an opening for brands that deliver on label claims and build trust.
Gruns' valuation reflects investor appetite for consumer health at scale. At $10M monthly revenue and $500M valuation, the company trades at a 5x revenue multiple. That is reasonable for a consumer brand with strong unit economics and proven product-market fit, though not exceptional for a high-growth startup. The low dilution suggests Gruns is largely self-funding growth and raising opportunistically rather than out of necessity.